MedPath

Durability of Antiviral Activity in Chronic HBV Patients Who Showed Complete Response in L-FMAU-301,302 or 303 Trial

Completed
Conditions
Hepatitis B
Registration Number
NCT00362674
Lead Sponsor
Bukwang Pharmaceutical
Brief Summary

The purpose of this study is to evaluate the durability of antiviral activity in chronic hepatitis B patients who showed complete response in L-FMAU-301,L-FMAU-302 or L-FMAU-303 trial.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  1. The patients who have completed L-FMAU-301, L-FMAU-302 or L-FMAU-303.
  2. Patients who have showed complete response (ALT normalization and HBV DNA <4,700 copies/mL in L-FMAU-301 or L-FMAU-302, in addition, HBeAg seroconverted to anti-HBe at the last two visits in L-FMAU-301) after completion of L-FMAU-301 or L-FMAU-302 and treated with the clevudine.
  3. Patients who have showed complete response (ALT normalization and HBV DNA <4,700 copies/mL, in addition HBeAg seroconverted to anti-HBe at the last two visits who showed HBeAg positiv at baseline) after completion of L-FMAU-303
  4. Patients who were able to give written informed consent prior to study start and to comply with the study requirements.
  5. Patients with bilirubin levels less than 2.0 mg/dL, prothrombin time of less than 1.7 (INR), and a serum albumin level of at least 3.5 g/dL at the last visit in L-FMAU-301, L-FMAU-302 or L-FMAU-303.
Exclusion Criteria
  1. Patients who have showed complete response but previously treated with placebo in the L-FMAU-301, L-FMAU-302.
  2. Patients who were currently receiving antiviral, immunomodulatory or corticosteroid therapy.
  3. Patients previously treated with interferon, lamivudine, lobucavir, famciclovir, adefovir or any other investigational nucleoside for HBV infection.
  4. Patients with a history of ascites, variceal hemorrhage or hepatic encephalopathy.
  5. Patients co-infected with HCV, HDV or HIV.
  6. Patients with a liver mass (hemangioma, nodule), biliary diseases except asymptomatic GB stone during the L-FMAU-301, L-FMAU-302 or L-FMAU-303.
  7. Patients who were pregnant or breast-feeding.
  8. Patients with a significant gastrointestinal, renal, hepatic (decompensated), biliary diseases except asymptomatic GB stone, bronchopulmonary, neurological, cardiovascular, oncologic or allergic disease. The patients with a benign tumor were excluded if judged by an investigator that the continuation of study would be interfered by benign tumor.
  9. Patients who were not suitable to the study if judged by an investigator.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (27)

Korea University Guro Hospital

๐Ÿ‡ฐ๐Ÿ‡ท

Seoul, Guro-gu, Korea, Republic of

Keimyumg University Dongsan Medical Center

๐Ÿ‡ฐ๐Ÿ‡ท

Jung-gu,, Daegu, Korea, Republic of

St. Holly Family Mary's Hospital

๐Ÿ‡ฐ๐Ÿ‡ท

Pucheon, Kyounggi-do, Korea, Republic of

Gil Medical Center

๐Ÿ‡ฐ๐Ÿ‡ท

Incheon, Namdong-Gu, Korea, Republic of

St. Mercy's Hospital

๐Ÿ‡ฐ๐Ÿ‡ท

Bupyoung-dong, Bupyoung-gu, Incheon, Korea, Republic of

Chonbuk National University Hospital

๐Ÿ‡ฐ๐Ÿ‡ท

Jeonju-city, Jeonbuk, Korea, Republic of

Wonkwang University Hospital

๐Ÿ‡ฐ๐Ÿ‡ท

Iksan-City, Jeonbuk, Korea, Republic of

Kangnam Sacred Heart Hospital

๐Ÿ‡ฐ๐Ÿ‡ท

Daelim-dong, Yongdeungpo-gu, Seoul, Korea, Republic of

Seoul National University Hospital

๐Ÿ‡ฐ๐Ÿ‡ท

Seoul, Jongno-Gu, Korea, Republic of

National Cancer Center

๐Ÿ‡ฐ๐Ÿ‡ท

Ilsan-gu, Kyounggi-do, Korea, Republic of

Pochon CHA University Hospital

๐Ÿ‡ฐ๐Ÿ‡ท

Seongnam-gu, Kyounggi-do, Korea, Republic of

Nowon Eulji Hospital

๐Ÿ‡ฐ๐Ÿ‡ท

Hagye 1-dong, Nowon-gu, Seoul, Korea, Republic of

Seoul Paik Hospital

๐Ÿ‡ฐ๐Ÿ‡ท

Jeo-dong, Seoul, Korea, Republic of

Ehwa Womans University Mokdong Hospital

๐Ÿ‡ฐ๐Ÿ‡ท

Mok-dong, Yangcheon-gu, Seoul, Korea, Republic of

Korea Cancer Center Hospital

๐Ÿ‡ฐ๐Ÿ‡ท

Gongneung-dong, Nowon-gu, Seoul, Korea, Republic of

Samsung Medical Center

๐Ÿ‡ฐ๐Ÿ‡ท

Ilwon-dong, Songpa-gu, Seoul, Korea, Republic of

Seoul Asan Medical Center

๐Ÿ‡ฐ๐Ÿ‡ท

Pungnap-dong, Kangnam-gu, Seoul, Korea, Republic of

Kangbuk Samsung Hospital

๐Ÿ‡ฐ๐Ÿ‡ท

Pyoung-dong, Chongro-gu,, Seoul, Korea, Republic of

Severance Hospital

๐Ÿ‡ฐ๐Ÿ‡ท

Shinchon- dong, Seodaemun-gu, Seoul, Korea, Republic of

St. Vincent's Hospital

๐Ÿ‡ฐ๐Ÿ‡ท

Ji-dong,, Paldal-gu, Suwon, Korea, Republic of

St. Mary's Hospital

๐Ÿ‡ฐ๐Ÿ‡ท

Seoul, Yungdungpo-Gu, Korea, Republic of

Inha University Hospital

๐Ÿ‡ฐ๐Ÿ‡ท

Sinhung-dong, Jung-gu, Incheon, Korea, Republic of

Pusan National University Hospital

๐Ÿ‡ฐ๐Ÿ‡ท

Ami-dong, Seo-gu, Pusan, Korea, Republic of

Kosin Medical Center

๐Ÿ‡ฐ๐Ÿ‡ท

Amnam-dong, Seo-gu, Pusan, Korea, Republic of

Korea University Anam Hospital

๐Ÿ‡ฐ๐Ÿ‡ท

Anam-dong, Sungbuk-ku, Seoul, Korea, Republic of

Yongdong Severance Hospital

๐Ÿ‡ฐ๐Ÿ‡ท

Dogok-dong, Kangnam-gu, Seoul, Korea, Republic of

Yeungnam University Medical Center

๐Ÿ‡ฐ๐Ÿ‡ท

Daemyoung-dong, Nam-gu, Taegu, Korea, Republic of

ยฉ Copyright 2025. All Rights Reserved by MedPath